Sotagliflozin|1018899-04-1|-陌孚医药/Medlife

您当前的位置：

Sotagliflozin

目录号: PL11762 纯度: ≥98%

Sotagliflozin (LX-4211) 是SGLT1/2抑制剂，是抗糖尿病剂。

CAS No. :1018899-04-1

商品编号	规格	价格	会员价
PL11762-2mg	2mg	¥964.00	请登录
PL11762-5mg	5mg	¥2817.50	请登录
PL11762-10mg	10mg	¥4952.50	请登录
PL11762-25mg	25mg	¥10027.50	请登录
PL11762-50mg	50mg	¥10286.00	请登录
PL11762-100mg	100mg	询价	询价
PL11762-200mg	200mg	询价	询价
PL11762-10mM*1mLinDMSO	10mM*1mLinDMSO	¥1652.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Sotagliflozin
中文别名	(2S,3R,4R,5S,6R)-2-(4-氯-3-(4-乙氧基苄基)苯基)-6-(甲基硫代)四氢-2H-吡喃-3,4,5-三醇;(2S,3R,4R,5S,6R)-2-(4-氯-3-(4-乙氧基苄基)苯基)-6-(甲硫基)四氢-2H-吡喃-3,4,5 - 三醇;LX4211 抑制剂;苯基磺酰氨甲基三氟硼酸钾;索格列净;糖4211;(2S,3R,4R,5S,6R)-2-(4-氯-3-(4-乙氧基苄基)苯基)-6-(;2抑制剂;LX4211, 一种SGLT1;LX-4211
英文名称	Sotagliflozin
英文别名	(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol;LP 802034;LX4211;Sotagliflozin (LX4211);(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol;(2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylsulfanyl-tetrahydro-pyran-3,4,5-triol;CS-1069;LP-802034;Sotagliflozin;UNII-6B4ZBS263Y;LX-4211;SOTA-009;(5S)-Methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-beta-L-xylopyranoside;LX421;EOS-61381;LX4211 - L10525;LX-4211 (sotagliflozin);Zabofloxacin Hydrochloride;6B4ZBS263Y;beta-l-Xylopyranoside, methyl 5-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5S)-;b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-;b-L-Xylopyranoside, methyl 5-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-thio-, (5S)-;Sotaglifloz
Cas No.	1018899-04-1
分子式	C₂₁H₂₅ClO₅S
分子量	424.94
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

Sotagliflozin (LX-4211) 是SGLT1/2抑制剂，是抗糖尿病剂。

生物活性

Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

性状

Solid

IC50 & Target[1][2]

SGLT1/2

体外研究(In Vitro)

LX4211 enhanced urinary glucose excretion by inhibiting SGLT2-mediated renal glucose reabsorption; markedly and significantly improved multiple measures of glycemic control, including fasting plasma glucose, oral glucose tolerance, and HbA(1c); and significantly lowered serum triglycerides. LX4211 also mediated trends for lower weight, lower blood pressure, and higher glucagon-like peptide-1 levels. In a follow-up single-dose study in 12 patients with T2DM, LX4211 (300 mg) significantly increased glucagon-like peptide-1 and peptide YY levels relative to pretreatment values, probably by delaying SGLT1-mediated intestinal glucose absorption [1]. LX4211-treated mice and SGLT1-/- mice also had increased GLP-1 AUC values, decreased glucose-dependent insulinotropic polypeptide (GIP) AUC values, and decreased blood glucose excursions during the 6 hours after a challenge with oral glu

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Zambrowicz B, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
[2]. Powell DR, et al. LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013 May;345(2):250-9.

溶解度数据	In Vitro: DMSO : ≥ 100 mg/mL (235.33 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation